Trevi Therapeutics (TRVI) After Fresh Loss Figures Is The Undervalued Story Still Intact

Trevi Therapeutics (TRVI) just released updated figures, reporting a third quarter net loss of US$21.45 million and a nine month loss of US$52.44 million, giving investors new context for the recent share performance.

The fresh loss numbers land at a time when Trevi Therapeutics shares have been volatile, with a 1-day share price return of 6.84% and a 7-day move of 12.33%. This has lifted the current price to US$15.31 following a 90-day decline of 13.99% and a 1-year total shareholder return of 31.19%.

Scan how Trevi Therapeutics fits alongside other high potential opportunities by comparing it with our hand picked list of 19 high quality undiscovered gems in similar high risk, early stage stories.

Trevi Therapeutics now trades well below the average analyst price target after a sharp recent bounce. Is that a genuine discount, or a warning that the market’s caution on a loss-making biotech is justified?

Most Popular Narrative: 46% Undervalued

Trevi Therapeutics closed at $15.31, while the analyst consensus Narrative on Simply Wall St points to a fair value of $28.18 that anchors on a higher long term earnings profile and uses a 7.24% discount rate.

Parallel development of multiple chronic cough indications, including refractory chronic cough with a Phase IIb dose ranging trial, creates several potential data readouts from the same core asset. This can increase the number of possible label expansions over time and influence long term earnings power if approvals follow.

See why 1 investors see Trevi Therapeutics as 46% undervalued.

Result: Fair Value of $28.18 (UNDERVALUED)

Still, the entire Trevi Therapeutics story leans on Haduvio, so any trial setback or fresh funding need could quickly challenge that 46% undervalued narrative.

Find out about the key risks to this Trevi Therapeutics narrative.

Another View on Trevi Therapeutics Valuation

The analyst fair value story for Trevi Therapeutics leans heavily on long dated earnings, yet the current P/B of 6.8x is far higher than both US pharmaceuticals peers at 2.5x and the sector average at 1.9x. That kind of premium loads more risk onto a loss making stock. How comfortable are you paying up front for outcomes that still depend on Haduvio trials and future funding?

For a closer look at what this gap might imply for future repricing, see what the numbers say in our valuation breakdown: See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Does this Trevi Therapeutics story feel optimistic or too stretched for the risks on the table? Act while the information is fresh and weigh the red flags against your own thesis by checking the 4 important warning signs.

Looking for more investment ideas beyond Trevi Therapeutics?

If Trevi Therapeutics has sharpened your focus on risk and reward, broaden your watchlist with other angles so you are not relying on a single story.

• Chase higher potential upside in the small cap arena by checking out 11 elite penny stocks with strong financials before the crowd catches on.
• Stack the odds toward better value by using the 33 high quality undervalued stocks to spot businesses that still trade below their estimated worth.
• Balance risk with resilience by scanning the 30 resilient stocks with low risk scores and line up candidates that may better handle rough patches.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com